Hepatitis Inequalities Study
Overcoming Inequalities in Health to Eliminate Hepatitis - Real-World Evidence from a Territory-Wide Cohort
1 other identifier
observational
100,000
0 countries
N/A
Brief Summary
Health inequality in liver diseases including age, gender, ethnicity and socioeconomic status has been increasingly recognised and potentially hinder hepatitis elimination. Health inequality has significant impact to evaluate the impact diagnostic and treatment uptake rates of chronic viral hepatitis on risk of hepatocellular carcinoma (HCC), hepatic event and liver-related death in patients with chronic hepatitis B and/or C. To overcome the limitation of small prospective cohort study of limited recruitment period, retrieving information from the Clinical Data Analysis and Reporting System (CDARS) from Hospital Authority (HA) will be one of the best way to answer these questions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2024
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 11, 2024
CompletedFirst Posted
Study publicly available on registry
September 19, 2024
CompletedStudy Start
First participant enrolled
October 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2031
September 19, 2024
July 1, 2024
6.3 years
September 11, 2024
September 16, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Safety
Time from diagnosis of hepatitis to treatment.
From 1 January 2000 to 31 March 2024
Secondary Outcomes (1)
Safety
From 1 January 2000 to 31 March 2024
Eligibility Criteria
From the Clinical Data Analysis and Reporting System (CDARS) from Hospital Authority
You may qualify if:
- Patients will be eligible if they have any of these viral markers (HBeAg / HBsAg / HBV DNA / HCV RNA) and/or any of the following diagnosis codes (ICD-9 070-070.9; 348.3, 349.82, 456, 456.2, 456.8, 567.2, 567.8, 570, 571.2, 571.5, 571.6, 572.2, 572.3, 572.4, 789.5) checked or coded in any public hospitals or clinics from 1 January 2000 to 31 March 2024.
You may not qualify if:
- Patients with missing age, gender, ethnicity and socioeconomic status
- (Subgroup analysis for ethnicity and socioeconomic status) Patients with missing ethnicity and socioeconomic status
- Serious medical illnesses or malignancy with life expectancy \<1 year
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May;142(6):1264-1273.e1. doi: 10.1053/j.gastro.2011.12.061.
PMID: 22537432BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
September 11, 2024
First Posted
September 19, 2024
Study Start
October 1, 2024
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
June 30, 2031
Last Updated
September 19, 2024
Record last verified: 2024-07